Mechanism of Action:**
- Synthetic analog of melanocortin peptide α-MSH
- Agonist of melanocortin receptors MC3R and MC4R in central nervous system
- Activates neurons in hypothalamus responsible for sexual behavior
- Increases dopaminergic activity in pleasure centers
Recommended for:
- Women with Hypoactive Sexual Desire Disorder (HSDD)
- Men with psychogenic erectile dysfunction
- Patients with libido decrease due to antidepressant use
- Individuals with age-related sexual function decline
Research and Studies:
Clinical studies demonstrate:
- Improvement in sexual desire in 70% of women with HSDD
- 60-80% increase in frequency of satisfactory sexual contacts
- Onset of action within 2-4 hours after subcutaneous administration
- Efficacy in 65% of patients with SSRI-induced sexual dysfunction
- FDA approval for HSDD treatment in women in 2019
- Hypoactive Sexual Desire Disorder in women
- Erectile dysfunction in men
- Libido decrease due to medication use
- Age-related sexual function disorders
- Psychogenic sexual dysfunctions
The drug is dissolved in 1 ml of sterile water for injections and administered subcutaneously in the abdominal area or thigh 2-4 hours before planned sexual activity. Recommended starting dose is 1-1.5 mg, if necessary the dose can be increased to 2 mg. Not recommended for use more than once daily.
Contraindications:
- Decompensated cardiovascular diseases
- Uncontrolled arterial hypertension
- Severe hepatic and renal dysfunction
- Pregnancy and lactation period
- Concurrent use of nitrates
Side Effects:
- Nausea and vomiting in first hours after administration
- Transient increase in blood pressure
- Headache and dizziness
- Redness and itching at injection site
- Skin hyperpigmentation with long-term use
